SCHEMBL8953772

SCHEMBL8953772

COC(=O)c1ccnc(C(C)C)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.57
KDM4C Q9H3R0 2/20 0.57
KDM6B O15054 1/20 0.57
KDM5C P41229 1/20 0.57
KDM2A Q9Y2K7 1/20 0.57
KDM3A Q9Y4C1 1/20 0.57
ALOX15 P16050 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
JMJD6 Q6NYC1 1/20 0.50
HTT P42858 1/20 0.46
HPGD P15428 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
XDH P47989 1/20 0.44
CA9 Q16790 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25933766 0.88 KDM4E (0.55) KDM4EKDM4CKDM6BKDM5CKDM2A
SCHEMBL6918592 0.87 KDM4E (0.58) KDM4EKDM4CKDM6BKDM5CKDM2A
SCHEMBL18547226 0.87 KDM4E (0.54) KDM4EKDM4CKDM6BKDM5CKDM2A
SCHEMBL20072588 0.85 KDM4E (0.53) KDM4EKDM4CKDM6BKDM5CKDM2A
SCHEMBL580680 0.85 KDM4E (0.55) KDM4EKDM4CKDM6BKDM5CKDM2A
SCHEMBL5208579 0.85 KDM4E (0.55) KDM4EKDM4CKDM6BKDM5CKDM2A
SCHEMBL25341704 0.84 KDM4E (0.51) KDM4EKDM4CKDM6BKDM5CKDM2A
SCHEMBL29139910 0.84 KDM4E (0.51) KDM4EKDM4CKDM6BKDM5CKDM2A
SCHEMBL14063563 0.84 CDK8 (0.51) KDM4EKDM4CKDM6BKDM5CKDM2A
SCHEMBL28976339 0.82 KDM4E (0.53) KDM4EKDM4CKDM6BKDM5CKDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11225469-B2 Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2022-01-18 US disclosed
US-20180105508-A1 INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2018-04-19 US disclosed
US-20180105508-A1 INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2018-04-19 US disclosed
US-9938276-B2 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2018-04-10 US disclosed
US-9938276-B2 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2018-04-10 US disclosed
US-20170320874-A1 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2017-11-09 US disclosed
US-20170320874-A1 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2017-11-09 US disclosed
US-9617246-B2 Thioether-piperidinyl orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-04-11 US disclosed
US-8486950-B2 Janus kinase inhibitor compounds and methods F. HOFFMANN-LA ROCHE AG (CH) 2013-07-16 US disclosed
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2013-04-18 US disclosed
US-8188085-B2 Antifungal agents MERCK SHARP & DOHME CORP. (US) 2012-05-29 US disclosed
US-20110230465-A1 VIRAL POLYMERASE INHIBITORS BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2011-09-22 US disclosed
US-20100317643-A1 JANUS KINASE INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2010-12-16 US disclosed
US-20100240657-A1 CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100113439-A1 Antifungal agents MERCK & CO., INC. (US) 2010-05-06 US disclosed
WO-2009003998-A2 ANTIPROLIFERATIVE COMPOUNDS BASED ON 5-MEMBERED HETEROCYCLES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE TYK2, IRAK1, IRAK4 KDM4E 1375/4885KDM4C 1053/4885KDM6B 690/4885
US-11225469-B2 Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof PHGDH, PGD, PGK1 KDM4E 3565/4885KDM4C 4369/4885KDM6B 4160/4885
US-20100317643-A1 JANUS KINASE INHIBITOR COMPOUNDS AND METHODS JAK2, JAK1, JAK3 KDM4E 572/4885KDM4C 1042/4885KDM6B 653/4885
US-20100113439-A1 Antifungal agents GMDS, GBA3, UGGT1 KDM4E 3990/4885KDM4C 3973/4885KDM6B 3218/4885
US-20180105508-A1 INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF PHGDH, PGD, PGK1 KDM4E 3608/4885KDM4C 4315/4885KDM6B 4234/4885
US-20170320874-A1 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY5R KDM4E 1904/4885KDM4C 1819/4885KDM6B 1894/4885
US-20100240657-A1 CHEMICAL COMPOUNDS CCNA1, CCNT1, MKI67 KDM4E 1674/4885KDM4C 985/4885KDM6B 2108/4885
US-20110230465-A1 VIRAL POLYMERASE INHIBITORS POLR2A, POLR2H, POLR2E KDM4E 3158/4885KDM4C 2783/4885KDM6B 1791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.